Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-861 phase 3 study in narcolepsy type 1 with cataplexy
NL-OMON58870Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of oveporexton in narcolepsy type 1 (NT1), sponsored by Takeda. Primary endpoint: Change from baseline to Week 12 in Epworth Sleepiness Scale total score. Started Sep 2024; status: completed.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NL-OMON58870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58870.